Department of Clinical Oncology, Prince of Wales Hospital, Sir YK Pao Centre for Cancer, Faculty of Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital, NT, Hong Kong, Hong Kong Special Administrative Region, China.
Hong Kong Cancer Institute, State Key Laboratory of Translational Oncology, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, Hong Kong Special Administrative Region, China.
Health Qual Life Outcomes. 2020 Feb 10;18(1):24. doi: 10.1186/s12955-020-1283-x.
For young premenopausal breast cancer patients, adjuvant chemotherapy may cause menstrual disruptions and premature menopause, which may in turn impair their quality of life (QoL). In this study among young breast cancer survivors who have undergone adjuvant chemotherapy, the objectives were to assess post-treatment menopausal symptoms and their associated factors, and to correlate these symptoms with breast cancer-specific QoL.
The study population included premenopausal young Chinese women with early-stage breast cancer who had undergone adjuvant chemotherapy between 3 and 10 years prior to enrolling into this study. At study entry, patients' characteristics and clinical features were collected; each patient had detail menstrual history collected and each filled in MENQOL and FACT-B + 4 questionnaires.
Two hundred eighty eligible patients were recruited. For adjuvant chemotherapy, 92% received anthracyclines and 28% received taxanes; 76% received adjuvant tamoxifen. At a median of 5.0 years from initial cancer diagnosis, 49 and 11% had become post- and peri-menopausal respectively. MENQOL at study entry revealed that physical domain score was worse in overweight/obese patients (mean scores for underweight/normal vs overweight/obese: 2.65 vs 2.97, p = 0.0162). Vasomotor domain score was worse in those who received taxanes or tamoxifen (taxane vs non-taxane: 2.91 vs. 2.35, p = 0.0140; tamoxifen vs no tamoxifen: 2.75 vs. 2.34, p = 0.0479). Sexual domain score was worse among those who had become peri/post-menopausal (peri/postmenopausal vs premenopausal: 2.82 vs. 2.29, p = 0.0229). On the other hand, patients who utilized traditional Chinese medicine had significantly worse scores for vasomotor, psychosocial and physical domains. Further, there was a significant association between MENQOL scores and FACT-B + 4 scores; less severe symptoms in the MENQOL domains were associated with better QoL scores in FACT-B + 4 physical, functional, psychosocial and emotional well-being, Breast Cancer Subscale, Arm Subscale and FACT-B total score.
Among premenopausal breast cancer women who had undergone adjuvant chemotherapy, those who had received taxanes or tamoxifen, were overweight/obese and utilized traditional Chinese medicine had more severe menopausal symptoms. Patients who experienced worse menopausal symptoms were found to have worse breast cancer-specific QoL. Interventional studies with an aim to alleviate menopausal symptoms are warranted to assess if overall QoL of these patients could be improved.
Not applicable.
对于年轻的绝经前乳腺癌患者,辅助化疗可能会导致月经紊乱和过早绝经,进而影响其生活质量(QoL)。在这项针对接受辅助化疗的年轻乳腺癌幸存者的研究中,目的是评估治疗后绝经症状及其相关因素,并将这些症状与乳腺癌特异性 QoL 相关联。
研究人群包括接受辅助化疗的 3 至 10 年前确诊为早期乳腺癌的年轻绝经前中国女性。在研究入组时,收集了患者的特征和临床特征;每位患者均详细记录了月经史,并填写了 MENQOL 和 FACT-B+4 问卷。
共招募了 280 名符合条件的患者。对于辅助化疗,92%的患者接受了蒽环类药物治疗,28%的患者接受了紫杉烷类药物治疗;76%的患者接受了辅助他莫昔芬治疗。从初始癌症诊断开始的中位数为 5.0 年后,49%和 11%的患者分别进入绝经后和围绝经期。在研究入组时,MENQOL 显示超重/肥胖患者的生理领域评分较差(体重不足/正常与超重/肥胖的平均得分:2.65 与 2.97,p=0.0162)。接受紫杉烷类药物或他莫昔芬治疗的患者血管舒缩域评分较差(紫杉烷类药物与非紫杉烷类药物:2.91 与 2.35,p=0.0140;他莫昔芬与无他莫昔芬:2.75 与 2.34,p=0.0479)。进入围绝经期/绝经后的患者性领域评分较差(围绝经期/绝经后与绝经前:2.82 与 2.29,p=0.0229)。另一方面,接受中医药治疗的患者血管舒缩、心理社会和生理领域的评分明显较差。此外,MENQOL 评分与 FACT-B+4 评分之间存在显著相关性;MENQOL 各领域症状较轻与 FACT-B+4 身体、功能、心理社会和情绪健康、乳腺癌亚量表、手臂亚量表和 FACT-B 总分的 QoL 评分较好相关。
在接受辅助化疗的年轻绝经前乳腺癌女性中,接受紫杉烷类药物或他莫昔芬治疗、超重/肥胖和接受中医药治疗的患者绝经症状更严重。经历更严重绝经症状的患者发现乳腺癌特异性 QoL 更差。有必要进行干预性研究以减轻绝经症状,评估这些患者的整体 QoL 是否可以得到改善。
不适用。